Regeneron and Tessera partner to develop gene therapy for AATD

Uncategorized / By admin22

Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to advance a promising in vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD).